Log in

Relevant bibliographies by topics / PSA / Journal articles

To see the other types of publications on this topic, follow the link: PSA.

Journal articles on the topic 'PSA'

Author: Grafiati

Published: 4 June 2021

Last updated: 25 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'PSA.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

CAULI, ALBERTO, DAFNA D. GLADMAN, ALESSANDRO MATHIEU, et al. "Patient Global Assessment in Psoriatic Arthritis: A Multicenter GRAPPA and OMERACT Study." Journal of Rheumatology 38, no. 5 (2011): 898–903. http://dx.doi.org/10.3899/jrheum.100857.

Full text

Abstract:

Objective.During OMERACT 8, delegates selected patient global assessment (PGA) of disease as a domain to be evaluated in randomized controlled trials in psoriatic arthritis (PsA). This study assessed the reliability of the PGA, measured by means of 0–100 mm visual analog scale (VAS), and the additional utility of separate VAS scales for joints (PJA) and skin (PSA).Methods.In total, 319 consecutive patients with PsA (186 men, 133 women, mean age 51 ± 13 yrs) were enrolled. PGA, PJA, and PSA were administered at enrolment (W0) and after 1 week (W1). Detailed clinical data, including ACR joint co

APA, Harvard, Vancouver, ISO, and other styles

2

Oldenburg, Jan, Johan Lars Bjerner, Lara Pasovic, et al. "The performance of prostate specific antigen (PSA) testing in the population based NPCC cohort." Journal of Clinical Oncology 41, no. 16_suppl (2023): 5029. http://dx.doi.org/10.1200/jco.2023.41.16_suppl.5029.

Full text

Abstract:

5029 Background: Prostate cancer (PCa) screening using prostate-specific antigen (PSA) is controversial. Benign prostate hyperplasia increases PSA in aging men independent of PCa such that PSA’s test performance differs between younger and older men. Age-specific cut-off values might therefore be advisable. The large Norwegian Prostate Cancer Consortium (NPCC) database might be able to contribute with clinically relevant information on age-specific PSA cut-off values. Methods: The Norwegian Prostate Cancer Consortium (NPCC) collected 8 857 761 PSA tests from 1.291.151 men. Results were linked

APA, Harvard, Vancouver, ISO, and other styles

3

Zhang, Wan-Ming, Patrik Finne, Jari Leinonen, Satu Vesalainen, Stig Nordling та Ulf-HÅkan Stenman. "Measurement of the Complex between Prostate-specific Antigen and α1-Protease Inhibitor in Serum". Clinical Chemistry 45, № 6 (1999): 814–21. http://dx.doi.org/10.1093/clinchem/45.6.814.

Full text

Abstract:

Abstract Background: Prostate-specific antigen (PSA) occurs in serum both free and in complex with protease inhibitors. The complex with α1-antichymotrypsin (ACT) is the major form in serum, and the proportion of PSA-ACT is higher in prostate cancer (PCa) than in benign prostatic hyperplasia (BPH). PSA also forms a complex with α1-protease inhibitor (API) in vitro, and the PSA-ACT complex has been detected in serum from patients with prostate cancer. The aim of the present study was to develop a quantitative method for the determination of PSA-API and to determine the serum concentrations in p

APA, Harvard, Vancouver, ISO, and other styles

4

Balk, Steven P., Yoo-Joung Ko, and Glenn J. Bubley. "Biology of Prostate-Specific Antigen." Journal of Clinical Oncology 21, no. 2 (2003): 383–91. http://dx.doi.org/10.1200/jco.2003.02.083.

Full text

Abstract:

Prostate-specific antigen (PSA) is an androgen-regulated serine protease produced by both prostate epithelial cells and prostate cancer (PCa) and is the most commonly used serum marker for cancer. It is a member of the tissue kallikrein family, some of the members of which are also prostate specific. PSA is a major protein in semen, where its function is to cleave semenogelins in the seminal coagulum. PSA is secreted into prostatic ducts as an inactive 244–amino acid proenzyme (proPSA) that is activated by cleavage of seven N-terminal amino acids. PSA that enters the circulation intact is rapi

APA, Harvard, Vancouver, ISO, and other styles

5

Joshi, S., M. A. Tilak, and S. Jadhav. "SIGNIFICANCE OF DETECTION OF FREE/TOTAL PSA RATIO AND OTHER BIOCHEMICAL PARAMETERS IN PATIENTS WITH BPH, CARCINOMA PROSTATE AND ITS CLINICOPATHOLOGIC CORRELATION." International Journal of Medicine and Medical Research 7, no. 1 (2021): 42–50. http://dx.doi.org/10.11603/ijmmr.2413-6077.2021.1.12122.

Full text

Abstract:

Background. Benign prostatic hyperplasia (BPH) can raise prostate-specific antigen (PSA) levels two to three times higher than the normal level. An increased PSA level does not indicate Prostate Cancer (PCa), but the higher the PSA level, the higher the chance of having PCa. Detection and treatment have been profoundly affected by the advent of Free/Total PSA ratio testing. Objectives. The aim of the study was to estimate free, total PSA levels and its ratio for serum levels of calcium, acid phosphatase and alkaline phosphatase in patients with BPH and PCa; to correlate clinical, biochemical a

APA, Harvard, Vancouver, ISO, and other styles

6

Tsakaldimis, Georgios, Dimitrios Diamantidis, Stavros Lailisidis, et al. "Evaluating the Diagnostic Role of the Testosterone-to-Prostate-Specific Antigen Ratio in Pre-Biopsy Risk Stratification of Prostate Cancer." Journal of Clinical Medicine 14, no. 9 (2025): 3022. https://doi.org/10.3390/jcm14093022.

Full text

Abstract:

Background: The testosterone-to-PSA (T/PSA) ratio has been proposed as a novel biomarker to enhance the diagnostic specificity of prostate-specific antigen (PSA) in prostate cancer (PCa) detection. The objective of this study was to evaluate the diagnostic performance of the T/PSA ratio in distinguishing PCa from benign conditions in men undergoing prostate biopsy. Materials and Methods: Eighty men who underwent systematic and targeted transrectal prostate biopsy were retrospectively studied. Clinical variables included serum PSA, testosterone, prostate volume, PSA density (PSAD), and the T/PS

APA, Harvard, Vancouver, ISO, and other styles

7

Jung, K., C. Stephan, M. Lein, et al. "Analytical performance and clinical validity of two free prostate-specific antigen assays compared." Clinical Chemistry 42, no. 7 (1996): 1026–33. http://dx.doi.org/10.1093/clinchem/42.7.1026.

Full text

Abstract:

Abstract We compared two recently introduced commercial assays (CanAg and Immulite) for measuring free prostate-specific antigen (f-PSA), total PSA (t-PSA), and the ratio of t-PSA/f-PSA (f-PSA%) in control materials and sera of 54 healthy men, 50 patients with benign prostatic hyperplasia (BPH), and 45 patients with prostate cancer (PCa). The lower detection limits for f-PSA were 0.038 microgram/L and 0.004 microgram/L for the CanAg and Immulite assays, respectively. The within-run and between-day precisions of the Immulite assay were &lt; 5%; the CanAg assay showed a poorer precision. Whe

APA, Harvard, Vancouver, ISO, and other styles

8

Rai, Samarpit, Nicola Pavan, Nachiketh Soodana-Prakash, et al. "Defining the optimal PSA range for the maximal predictive efficacy of PSA density to detect prostate cancer on biopsy: Results from a multi-institutional and prospective contemporary cohort." Journal of Clinical Oncology 34, no. 2_suppl (2016): 70. http://dx.doi.org/10.1200/jco.2016.34.2_suppl.70.

Full text

Abstract:

70 Background: PSA density (PSAD) is an important predictor of prostate cancer (PCa). We assessed whether the predictive accuracy of PSAD varied based on the range of PSA or whether the patient had a previous negative prostate biopsy (PB). Methods: We assessed a prospective cohort of men who were referred for a PB due to suspicion of PCa at 26 different sites across USA. The area under the receiver operating characteristic curve (AUC) was used to assess the added predictive accuracy of PSAD versus PSA across 3 different PSA ranges ( < 4, 4 – 10, > 10 ng/mL) and in men with or without a p

APA, Harvard, Vancouver, ISO, and other styles

9

Zhu, Lei, Hannu Koistinen, Ulf Landegren та Ulf-Håkan Stenman. "Proximity Ligation Measurement of the Complex between Prostate Specific Antigen and α1-Protease Inhibitor". Clinical Chemistry 55, № 9 (2009): 1665–71. http://dx.doi.org/10.1373/clinchem.2009.127779.

Full text

Abstract:

Abstract Background: Prostate specific antigen (PSA)–α1-protease inhibitor complex (PSA-API) is a minor form of PSA in serum. It may be useful for prostate cancer (PCa) diagnosis, but its specific detection is hampered by nonspecific background. To avoid this, we developed an immunoassay for PSA-API based on proximity ligation. Methods: We used a monoclonal antibody (mAb) to total PSA (tPSA) to capture PSA, while using another anti-tPSA mAb together with an anti-API mAb as probes. We measured PSA-API by quantification of amplified DNA strands conjugated to the probes. We measured serum PSA-API

APA, Harvard, Vancouver, ISO, and other styles

10

Algotar, Amit Mohan, Mitchell Sokoloff, Chiu-Hsieh Hsu, Parminder Singh, and Steven Paul Stratton. "Negative association of smoking with PSA and PSA velocity." Journal of Clinical Oncology 31, no. 15_suppl (2013): e16060-e16060. http://dx.doi.org/10.1200/jco.2013.31.15_suppl.e16060.

Full text

Abstract:

e16060 Background: Smoking and obesity have been implicated in the pathogenesis of various chronic diseases and carcinogenic processes. However, their role in prostate cancer (PCa) & their association with important biomarkers such as prostate specific antigen (PSA) & PSA velocity (rate of PSA change over time) remains unresolved. This study investigates the association of these risk factors with PSA & PSA velocity (PSAV) in men at high risk for PCa. Methods: Data were obtained from 699 men participating in a Phase 3 clinical trial aimed at investigating the effect of selenium supp

APA, Harvard, Vancouver, ISO, and other styles

11

Caglayan, Volkan, Efe Onen, Sinan Avci, et al. "Lymphocyte-to-monocyte ratio is a valuable marker to predict prostate cancer in patients with prostate specific antigen between 4 and 10 ng/dl." Archivio Italiano di Urologia e Andrologia 90, no. 4 (2019): 270–75. http://dx.doi.org/10.4081/aiua.2018.4.270.

Full text

Abstract:

Objective: To evaluate the diagnostic value of serum inflammation markers derived from complete blood count in diagnosis of prostate cancer (PCa). Methods: We retrospectively analyzed the data of 621 patients who underwent prostate biopsy between March 2013 and April 2018. Age, prostate specific antigen (PSA), free PSA, platelet count, neutrophil count, lymphocyte count, monocyte count, prostate volume (PV) and pathology result of the patients were recorded. Patients were grouped as benign prostatic hyperplasia (BPH), prostatitis and PCa. Patients were also grouped according to PSA values, as

APA, Harvard, Vancouver, ISO, and other styles

12

Guo, Zhui-Feng, Fan Yang, Xu-Wei Lu, Jia-Wen Wu, Chang He, and Cong-Hui Han. "Significance of the prostate central gland and total gland volume ratio in the diagnosis of prostate cancer patients in the prostate specific antigen grey zone." Journal of International Medical Research 49, no. 7 (2021): 030006052110198. http://dx.doi.org/10.1177/03000605211019879.

Full text

Abstract:

Objective To explore the significance of the prostate central gland to total gland volume ratio (PVc/PV) in the diagnosis of prostate cancer (PCa) in patients with prostate specific antigen (PSA) levels in the grey zone (4–10 ng/ml). Methods This retrospective study enrolled patients that had undergone prostate biopsy. The volume of the prostate and the central prostate gland were measured. The differences in PSA, the ratio of free to total PSA (f/tPSA), PSA density (PSAD) and PVc/PV between the PCa and non-PCa groups were compared. Receiver operating characteristic curve analysis for PCa and

APA, Harvard, Vancouver, ISO, and other styles

13

Rai, Samarpit, Nachiketh Soodana-Prakash, Nicola Pavan, et al. "Can PSA density and free-to-total PSA ratio improve our ability to predict prostate cancer on biopsy? Results from a prospective, multi-institutional, and contemporary cohort." Journal of Clinical Oncology 34, no. 2_suppl (2016): 57. http://dx.doi.org/10.1200/jco.2016.34.2_suppl.57.

Full text

Abstract:

57 Background: Several studies have reported an increased value of PSA density (PSAD) and free−to−total PSA ratio (f/t PSA) over PSA alone in predicting prostate cancer (PCa). Despite this, they remain underutilized. This study analyzed a cohort of men referred for prostate biopsy (PB) to determine if PSAD and f/t PSA enhanced the prediction of any PCa and/or significant PCa (Gleason score ≥ 7) compared to PSA. Methods: 1,370 prospectively enrolled patients were referred for a PB across 26 urological centers. A phlebotomy was performed immediately prior to PB for PSA and f/t PSA measurement. P

APA, Harvard, Vancouver, ISO, and other styles

14

Zhang, Wan-Ming, Patrik Finne, Jari Leinonen та ін. "Characterization and immunological determination of the complex between prostate-specific antigen and α2-macroglobulin". Clinical Chemistry 44, № 12 (1998): 2471–79. http://dx.doi.org/10.1093/clinchem/44.12.2471.

Full text

Abstract:

Abstract Prostate-specific antigen (PSA) rapidly forms a complex with α2-macroglobulin (A2M) in vitro; however, PSA complexed with A2M (PSA-A2M) is not detected by conventional immunoassays for PSA because it is encapsulated by the A2M. In this study, we show that denaturation of PSA-A2M at high pH renders PSA immunoreactive. Part of the complexed PSA is released in free form and part remains bound to denatured A2M. These forms can be measured by a conventional immunoassay for PSA. This finding enabled us to design a dissociation assay for the detection of PSA-A2M, which was based on the remov

APA, Harvard, Vancouver, ISO, and other styles

15

Srinivasan, Srilakshmi, Carson Stephens, Emily Wilson, et al. "Prostate Cancer Risk-Associated Single-Nucleotide Polymorphism Affects Prostate-Specific Antigen Glycosylation and Its Function." Clinical Chemistry 65, no. 1 (2019): e1-e9. http://dx.doi.org/10.1373/clinchem.2018.295790.

Full text

Abstract:

Abstract BACKGROUND Genetic association studies have reported single-nucleotide polymorphisms (SNPs) at chromosome 19q13.3 to be associated with prostate cancer (PCa) risk. Recently, the rs61752561 SNP (Asp84Asn substitution) in exon 3 of the kallikrein-related peptidase 3 (KLK3) gene encoding prostate-specific antigen (PSA) was reported to be strongly associated with PCa risk (P = 2.3 × 10−8). However, the biological contribution of the rs61752561 SNP to PCa risk has not been elucidated. METHODS Recombinant PSA protein variants were generated to assess the SNP-mediated biochemical changes by

APA, Harvard, Vancouver, ISO, and other styles

16

Stanton, Whitney N., E. David Crawford, Paul Arangua, et al. "Evaluation of prostate cancer risk in men with PSA < 1.5." Journal of Clinical Oncology 36, no. 6_suppl (2018): 64. http://dx.doi.org/10.1200/jco.2018.36.6_suppl.64.

Full text

Abstract:

64 Background: Prostate Specific Antigen (PSA) screening remains controversial primarily because of over detection and treatment. There is an unmet clinical need to identify patients at increased risk for high-grade (HG – Gleason Score ≥7) prostate cancer (PCa) since PSA has low sensitivity. Combining PSA with well-validated prostate cancer biomarkers (PCM) can improve risk assessment. We investigated the performance of three PCMs (phi – prostate health index, 4KScore, and SelectMDx) on patients with PSA levels < 1.5 ng/mL that represent a “safe zone” where risk of any PCa is rare Methods:

APA, Harvard, Vancouver, ISO, and other styles

17

Orugbo, V. P., and M. Ntaji. "DISTRIBUTION OF AGE-SPECIFIC PROSTATE SPECIFIC ANTIGEN PROFILES IN MEN BETWEEN 40 AND 80 YEARS TESTED IN A UROLOGY CLINIC IN OGHARA, DELTA STATE, NIGERIA." African Journal of Health, Safety and Environment 3, no. 1 (2022): 11–18. http://dx.doi.org/10.52417/ajhse.v3i1.195.

Full text

Abstract:

Prostate cancer (PCa) is one of the most common cancers in men, and it is the leading cause of cancer deaths in the world today. PCa is detected via a Prostate Specific Antigen (PSA) test. PSA is a protein produced by malignant and noncancerous tissue in the prostate gland. Although PSA levels grow as a result of prostate cancer, a high PSA test result does not always mean a man has prostate cancer. Several studies have corroborated this assertion of the inability of elevated PSA levels to most effectively indicate carcinoma without necessarily following up with histological examination. This

APA, Harvard, Vancouver, ISO, and other styles

18

Nurmikko, Pauliina, Kim Pettersson, Timo Piironen, Jonas Hugosson, and Hans Lilja. "Discrimination of Prostate Cancer from Benign Disease by Plasma Measurement of Intact, Free Prostate-specific Antigen Lacking an Internal Cleavage Site at Lys145-Lys146." Clinical Chemistry 47, no. 8 (2001): 1415–23. http://dx.doi.org/10.1093/clinchem/47.8.1415.

Full text

Abstract:

Abstract Background: The proportion of free prostate-specific antigen (PSA) is higher in the sera of patients with benign prostatic hyperplasia compared with patients with prostate cancer (PCa). We developed an immunoassay that measures intact, free PSA forms (fPSA-I), but does not detect free PSA that has been internally cleaved at Lys145-Lys146 (fPSA-N), and investigated whether this form could discriminate patients with PCa from those without PCa. Methods: The assay for fPSA-I uses a novel monoclonal antibody (MAb) that does not detect PSA that has been internally cleaved at Lys145-Lys146.

APA, Harvard, Vancouver, ISO, and other styles

19

Rais-Bahrami, Soroush, Minhaj Siddiqui, Srinivas Vourganti, et al. "Diagnostic value of biparametric MRI as an adjunct to PSA-based detection of prostate cancer." Journal of Clinical Oncology 32, no. 4_suppl (2014): 193. http://dx.doi.org/10.1200/jco.2014.32.4_suppl.193.

Full text

Abstract:

193 Background: To determine the diagnostic yield of analyzing a fast, cost-conscious biparametric (T2 and diffusion-weighted) MRI (B-MRI) for prostate cancer (PCa) detection as an adjunct to to standard digital rectal exam (DRE) and prostate specific antigen (PSA)-based screening. Methods: Review of patients who were enrolled in a trial to undergo MP-MRI and MR/US fusion-guided prostate biopsy at our institution identified 143 men who underwent MP-MRI in addition to standard DRE and PSA-based PCa screening prior to any other prior prostate biopsy sessions. Patient demographics, DRE staging, P

APA, Harvard, Vancouver, ISO, and other styles

20

Goč, Sanja, and Miroslava Janković. "Evaluation of Molecular Species of Prostate-Specific Antigen Complexed with Immunoglobulin M in Prostate Cancer and Benign Prostatic Hyperplasia." Disease Markers 35 (2013): 847–55. http://dx.doi.org/10.1155/2013/923819.

Full text

Abstract:

This study was aimed at defining molecular species of prostate-specific antigen (PSA) in immune complexes with immunoglobulin M (IgM). Having in mind the oligoreactivity of IgM and its preference for carbohydrate antigens, there is the possibility that it can selectively recognize known PSA glycoisoforms. PSA-IgM complexes and free PSA fractions were separated from the sera of subjects with prostate cancer (PCa) and benign prostatic hyperplasia (BPH) by gel filtration and subjected to on-chip immunoaffinity and ion-exchange chromatography. PSA-immunoreactive species were detected using surface

APA, Harvard, Vancouver, ISO, and other styles

21

von Eyben, Finn Edler, Kalevi Kairemo, and Daniel S. Kapp. "Prostate-Specific Antigen as an Ultrasensitive Biomarker for Patients with Early Recurrent Prostate Cancer: How Low Shall We Go? A Systematic Review." Biomedicines 12, no. 4 (2024): 822. http://dx.doi.org/10.3390/biomedicines12040822.

Full text

Abstract:

Serum prostate-specific antigen (PSA) needs to be monitored with ultrasensitive PSA assays (uPSAs) for oncologists to be able to start salvage radiotherapy (SRT) while PSA is <0.5 µg/L for patients with prostate cancer (PCa) relapsing after a radical prostatectomy (RP). Our systematic review (SR) aimed to summarize uPSAs for patients with localized PCa. The SR was registered as InPLASY2023110084. We searched for studies on Google Scholar, PUBMED and reference lists of reviews and studies. We only included studies on uPSAs published in English and excluded studies of women, animals, sarcoido

APA, Harvard, Vancouver, ISO, and other styles

22

Jean, SOSSA, and AVAKOUDJO Dedjinnin Josue Georges. "The Prevalence and the Pathological Characteristics of the Prostate Cancer in 138 Consecutive Transrectal Ultrasonography-Guided Prostate Biopsies." SAS Journal of Surgery 9, no. 10 (2021): 553–56. http://dx.doi.org/10.36347/sasjs.2021.v07i10.006.

Full text

Abstract:

Objective: To determine the prevalence and pathological characteristics of the prostate cancer in our institution’s TRUS-guided prostate biopsied patients. Patients and method: The age, the PSA level and the pathological data were collected and analyzed by means of Excel 2010®. Concerned patients were those who had consecutively undergone a TRUS-guided prostate biopsy between October 17, 2013 and July 31, 2021. Results: Among 138 patients whose age ranged from 42 to 96 years (mean=65.7years), 81 or 58.7% had a PCa. 97,5% of those PCa were in patients with PSA>30ng/mL whereas 40.2% of them w

APA, Harvard, Vancouver, ISO, and other styles

23

Zhou, A. M., P. C. Tewari, B. I. Bluestein, G. W. Caldwell, and F. L. Larsen. "Multiple forms of prostate-specific antigen in serum: differences in immunorecognition by monoclonal and polyclonal assays." Clinical Chemistry 39, no. 12 (1993): 2483–91. http://dx.doi.org/10.1093/clinchem/39.12.2483.

Full text

Abstract:

Abstract Prostate-specific antigen (PSA) in serum is primarily complexed with alpha 1-antichymotrypsin (alpha 1-ACT). However, 12-15% of prostate cancer (PCa) patients present with the predominant form being uncomplexed (free) PSA (Lilja et al., Clin Chem 1991;37:1618-24). We report that commercial immunoassays demonstrate variations in reactivity, especially to the uncomplexed form. We fractionated and analyzed commercial controls, PSA complexes prepared in vitro, and sera from patients with PCa or benign prostatic hyperplasia, using molecular sieve chromatography and Hybritech Tandem-R, Abbo

APA, Harvard, Vancouver, ISO, and other styles

24

Lee, Hahn-Ey, ByungWon Kim, Hyun Sik Yoon, Jungyo Suh, and Seung-June Oh. "Outcome of Patients With Elevated Prostate-Specific Antigen and Lower Urinary Tract Symptoms Receiving Holmium Laser Enucleation of the Prostate." International Neurourology Journal 26, no. 3 (2022): 248–57. http://dx.doi.org/10.5213/inj.2244176.088.

Full text

Abstract:

Purpose: This study investigated functional outcomes in lower urinary tract symptoms (LUTS), the incidence of incidental prostate cancer (PCa), and changes in prostate-specific antigen (PSA) levels after holmium laser enucleation of the prostate (HoLEP) in patients with elevated PSA and benign prostatic hyperplasia (BPH).Methods: A retrospective review of a prospectively designed protocol for patients who underwent HoLEP at our institution from January 2010 to May 2020 was conducted. Patients were classified into low-PSA (<3.0 ng/mL) and high-PSA (≥3.0 ng/mL) groups at baseline. Follow-up f

APA, Harvard, Vancouver, ISO, and other styles

25

Zani, Danilo, Silvia Costa, Lorenzo Gatti, et al. "The Association of PSA-IGM and Total PSA Improves the Diagnosis of Prostate Cancer." International Journal of Biological Markers 24, no. 3 (2009): 212. http://dx.doi.org/10.1177/172460080902400338.

Full text

Abstract:

Background and aim The specific causes of prostate cancer (Pca) are unknown but the main risk factors of tumor development are associated with age, genetic factors, ethnicity, diet and lifestyle. Prostate cancer is rare in men under 45 years of age, but becomes more common with advancing age. The main diagnostic tools for demonstrating the presence of PCa include digital rectal examination, transrectal ultrasonography, and serum measurement of prostate specific antigen (PSA) followed by prostate biopsy for confirmation of the diagnosis. While the measurement of PSA levels has revolutionized th

APA, Harvard, Vancouver, ISO, and other styles

26

Crawford, E. D., and J. Moul. "Use of PSA threshold to identify an increased 4-year risk of a prostate cancer diagnosis in U.S. men." Journal of Clinical Oncology 27, no. 15_suppl (2009): 5051. http://dx.doi.org/10.1200/jco.2009.27.15_suppl.5051.

Full text

Abstract:

5051 Background: Recent studies have shown that prostate specific antigen (PSA) values can be used to predict risk of developing prostate cancer (PCa) in the future. In the European Randomized Study of Screening for PCa (ERSPC) subjects with PSA of ≥1.5 ng/mL had a significantly greater risk of developing PCa after 4 years than subjects with PSA of <1.5 ng/mL (9.2% vs 1.5%, respectively; OR = 7.466; p < 0.001). This current analysis aimed to validate the ability of PSA of ≥1.5 ng/mL to predict the future risk of PCa in a US population of men within the Henry Ford Healthcare System (HFHS)

APA, Harvard, Vancouver, ISO, and other styles

27

Bhuyan, Soumitra S., Aastha Chandak, Niodita Gupta, et al. "Patient–Provider Communication About Prostate Cancer Screening and Treatment." American Journal of Men's Health 11, no. 1 (2016): 134–46. http://dx.doi.org/10.1177/1557988315614082.

Full text

Abstract:

The American Urological Association, American Cancer Society, and American College of Physicians recommend that patients and providers make a shared decision with respect to prostate-specific antigen (PSA) testing for prostate cancer (PCa). The goal of this study is to determine the extent of patient–provider communication for PSA testing and treatment of PCa and to examine the patient specific factors associated with this communication. Using recent data from the Health Information National Trends Survey, this study examined the association of patient characteristics with four domains of pati

APA, Harvard, Vancouver, ISO, and other styles

28

Hassan, Adel Hassan Mohamed, Tarek Huissen kamel, and Nesreen Ahmed Mosalam. "Correlation Between the Prostate-Specific Antigen Level and Bone Metastasis in Prostate Cancer. (Retrospective Study)." Journal of Cancer Research Reviews & Reports 2, no. 2 (2020): 1–6. http://dx.doi.org/10.47363/jcrrr/2020(2)113.

Full text

Abstract:

Background: The most common non-cutaneous malignancy for men is Prostate cancer (PCa). PCa diagnosed by biopsy and PSA detection. Bone metastasis (BM) causes a lot of complications, such as bone pain and pathological fracture that cause overall compromised quality of life. Bone scintigraphy (BS) is commonly used for monitoring and detection of (BM). Objective: To correlate between serum PSA level and BM in PCa patients on series of 250 patients through detecting PSA levels and BSs. Patients and Methods: In the present study Patients were stratified (group A) & (group B) according to BM. Ou

APA, Harvard, Vancouver, ISO, and other styles

29

Junker, Ralf, Burkhard Brandt, Christian Zechel, and Gerd Assmann. "Comparison of prostate-specific antigen (PSA) measured by four combinations of free PSA and total PSA assays." Clinical Chemistry 43, no. 9 (1997): 1588–94. http://dx.doi.org/10.1093/clinchem/43.9.1588.

Full text

Abstract:

Abstract We compared prostate-specific antigen (PSA) assay systems [i.e., free PSA (f-PSA) and the corresponding total PSA (t-PSA) assay] from four different manufacturers as well as the f-PSA/t-PSA ratios with regard to their ability to discriminate between benign prostate hyperplasia (BPH) and prostate cancer (PCA). ROC analysis showed similar areas under the curves (AUCs) with different assay systems. For the entire patient population the AUCs of the f-PSA/t-PSA ratio were not or slightly increased compared with the sole measurement of t-PSA (t-PSA, 0.792–0.820; f-PSA/t-PSA ratio, 0.685–0.8

APA, Harvard, Vancouver, ISO, and other styles

30

Fulla, Yvonne, Catherine Vuillemard, Maya Megarbane, et al. "Discordances entre les dosages de PSA : comparaison PSA, PSA libre, PSA complexé." Revue Française des Laboratoires 1999, no. 312 (1999): 85–90. http://dx.doi.org/10.1016/s0338-9898(99)80317-5.

Full text

APA, Harvard, Vancouver, ISO, and other styles

31

Lu-Yao, Grace L., Nikita Nikita, Scott W. Keith, et al. "Racial differences in long-term prostate cancer specific mortality following conservative management for low-risk prostate cancer: A population-based study." Journal of Clinical Oncology 37, no. 7_suppl (2019): 121. http://dx.doi.org/10.1200/jco.2019.37.7_suppl.121.

Full text

Abstract:

121 Background: It is uncertain whether the same criteria for active surveillance can be applied universally across races. This population-based study was undertaken to quantify racial differences in long-term risk of prostate cancer-specific mortality (PCSM) among patients with low-risk prostate cancer (PCa) receiving conservative management. Methods: We used the Surveillance, Epidemiology, and End Results (SEER) database to identify patients who had low-risk PCa (T1-T2a & Gleason 6 & PSA ≤ 10 ng/mL & N0 & M0) diagnosed in 2004 – 2015 and did not receive radical prostatectomy

APA, Harvard, Vancouver, ISO, and other styles

32

Logozzi, Mariantonia, Daniela F. Angelini, Alessandro Giuliani, et al. "Increased Plasmatic Levels of PSA-Expressing Exosomes Distinguish Prostate Cancer Patients from Benign Prostatic Hyperplasia: A Prospective Study." Cancers 11, no. 10 (2019): 1449. http://dx.doi.org/10.3390/cancers11101449.

Full text

Abstract:

Prostate Specific Antigen (PSA) fails to discriminate between benign prostatic hyperplasia (BPH) and Prostate Cancer (PCa), resulting in large numbers of unnecessary biopsies and missed cancer diagnoses. Nanovesicles called exosomes are directly detectable in patient plasma and here we explore the potential use of plasmatic exosomes expressing PSA (Exo-PSA) in distinguishing healthy individuals, BPH, and PCa. Exosomes were obtained from plasma samples of 80 PCa, 80 BPH, and 80 healthy donors (CTR). Nanoparticle Tracking Analysis (NTA), immunocapture-based ELISA (IC-ELISA), and nanoscale flow-c

APA, Harvard, Vancouver, ISO, and other styles

33

Zhu, Lei, Jari Leinonen, Wan-Ming Zhang, Patrik Finne та Ulf-Håkan Stenman. "Dual-Label Immunoassay for Simultaneous Measurement of Prostate-specific Antigen (PSA)-α1-Antichymotrypsin Complex Together with Free or Total PSA". Clinical Chemistry 49, № 1 (2003): 97–103. http://dx.doi.org/10.1373/49.1.97.

Full text

Abstract:

Abstract Background: A major portion of prostate-specific antigen exists in circulation as a complex with α1-antichymotrypsin (PSA-ACT), whereas a minor part is free (fPSA). The proportion of PSA-ACT is increased in prostate cancer (PCa), but immunologic determination of PSA-ACT is hampered by a background produced by nonspecific adsorption of ACT to the solid phase. To reduce the nonspecific interference, we produced an antibody specific for complexed ACT and developed immunofluorometric assays (IFMAs) for simultaneous measurement of fPSA + PSA-ACT (fPSA/PSA-ACT) and PSA-ACT + total PSA (tPSA

APA, Harvard, Vancouver, ISO, and other styles

34

Jayalath, Viranda H., Katherine Lajkosz, Neil E. Fleshner, Robert J. Hamilton, and David J. A. Jenkins. "The effect of lowering cholesterol through diet on serum prostate-specific antigen levels: A secondary analysis of clinical trials." Canadian Urological Association Journal 16, no. 8 (2022): 279–82. http://dx.doi.org/10.5489/cuaj.7975.

Full text

Abstract:

Importance: Statins appear to lower serum prostate-specific antigen (PSA) and improve prostate cancer (PCa) outcomes through cholesterol-dependent and independent mechanisms. While dietary modifications have an established role in serum cholesterol reduction, whether diet-driven cholesterol reductions yield similar PCa benefits to that observed with statins is unclear. We aimed to study the effect of diet-driven cholesterol reduction on serum PSA and estimated-PCa risk. Methods: A total of 291 men from six published randomized controlled trials of dietary interventions were included. Men were

APA, Harvard, Vancouver, ISO, and other styles

35

Herrera-Caceres, Jaime Omar, Eduardo Gonzalez-Cuenca, Andrea G. Manzanera, et al. "Population based PSA screening in Mexico City." Journal of Clinical Oncology 35, no. 6_suppl (2017): 92. http://dx.doi.org/10.1200/jco.2017.35.6_suppl.92.

Full text

Abstract:

92 Background: Since the U.S. Preventive Task Force recommended against PSA screening in 2012, the polemic between the benefit of early detection and the risk of early overtreatment, has been heightened. Furthermore, in countries where diagnosis is delayed even in symptomatic men and resources are limited for treating advanced disease, the impact of limiting PSA screening may be greater resulting in a shorter incidence/mortality ratio. In Mexico PSA screening is not widely used and many men are never diagnosed with PCa. Thus, the true incidence of PCa is unknown and yet it is the number one ca

APA, Harvard, Vancouver, ISO, and other styles

36

Starostzik, Christine. "Weniger PCA-Diagnosen ohne PSA-Screening." Uro-News 24, no. 2 (2020): 48. http://dx.doi.org/10.1007/s00092-020-4063-3.

Full text

APA, Harvard, Vancouver, ISO, and other styles

37

Y.-M.D. "Pas de PSA à la maison !" Option/Bio 23, no. 478 (2012): 5. http://dx.doi.org/10.1016/s0992-5945(12)71013-9.

Full text

APA, Harvard, Vancouver, ISO, and other styles

38

Oto, Julia, Álvaro Fernández-Pardo, Montse Royo, et al. "A predictive model for prostate cancer incorporating PSA molecular forms and age." Scientific Reports 10, no. 1 (2020): 2463. https://doi.org/10.5281/zenodo.10647596.

Full text

Abstract:

The diagnostic specifcity of prostate specifc antigen (PSA) is limited. We aimed to characterize eight anti-PSA monoclonal antibodies (mAbs) to assess the prostate cancer (PCa) diagnostic utility of diferent PSA molecular forms, total (t) and free (f) PSA and PSA complexed to α1-antichymotrypsin (complexed PSA). MAbs were obtained by immunization with PSA and characterized by competition studies, ELISAs and immunoblotting. With them, we developed sensitive and specifc ELISAs for these PSA molecular forms and measured them in 301 PCa patients and 764 patients with

APA, Harvard, Vancouver, ISO, and other styles

39

Wu, Ping, Lei Zhu, Ulf-Håkan Stenman, and Jari Leinonen. "Immunopeptidometric Assay for Enzymatically Active Prostate-Specific Antigen." Clinical Chemistry 50, no. 1 (2004): 125–29. http://dx.doi.org/10.1373/clinchem.2003.026146.

Full text

Abstract:

Abstract Background: Determinations of certain forms of prostate-specific antigen (PSA) have been shown to increase the specificity for prostate cancer (PCa). One such variant, proteolytically active PSA, is a potentially useful tumor marker, but it is not specifically recognized by antibodies. Using phage display libraries, we previously identified a “family” of peptides that bind specifically to active PSA. We used these to develop an immunopeptidometric assay (IPMA) that specifically detects this form of PSA. Methods: Microtitration plates coated with a PSA antibody were used to capture PSA

APA, Harvard, Vancouver, ISO, and other styles

40

Ferraro, Simona, Marco Bussetti, Niccolò Bassani, et al. "Definition of Outcome-Based Prostate-Specific Antigen (PSA) Thresholds for Advanced Prostate Cancer Risk Prediction." Cancers 13, no. 14 (2021): 3381. http://dx.doi.org/10.3390/cancers13143381.

Full text

Abstract:

We defined prostate-specific antigen (PSA) thresholds from a well calibrated risk prediction model for identifying and excluding advanced prostate cancer (PCa). We retrieved 902 biopsied patients with a pre-biopsy PSA determination (Roche assay). A logistic regression model predictive for PCa including the main effects [i.e., PSA, age, histological evidence of glandular inflammation (GI)] was built after testing the accuracy by calibration plots and Hosmer-Lemeshow test for goodness of fit. PSA thresholds were derived by assuming a diagnostic sensitivity of 95% (rule-out) and 80% (rule-in) for

APA, Harvard, Vancouver, ISO, and other styles

41

Ko, Young Hwii, Byung-Hoon Kim, Wonho Jung, et al. "Delaying a Biopsy With Serial Prostate-Specific Antigen Checkup Helps to Identify a Significant Prostate Cancer: A Strategy to Evade Unnecessary Procedures." Korean Journal of Urological Oncology 20, no. 3 (2022): 177–85. http://dx.doi.org/10.22465/kjuo.2022.20.3.177.

Full text

Abstract:

Purpose: To differentiate a non-cancer-related temporary increase in prostate-specific antigen (PSA) triggering unnecessary biopsy, we intentionally delayed biopsy with a serial follow-up, then investigated the efficacy of this strategy in identifying a significant prostate cancer (PCa).Materials and Methods: Retrospective data of patients who initially presented with a suspicious level of serum PSA (3–20 ng/mL), managed using the delayed strategy, and then eventually underwent biopsy were obtained from 4 tertiary centers between 2018–2020.Results: The collected 271 subjects had a median (inte

APA, Harvard, Vancouver, ISO, and other styles

42

Jung, Klaus, Brigitte Brux, Michael Lein, et al. "Molecular Forms of Prostate-specific Antigen in Malignant and Benign Prostatic Tissue: Biochemical and Diagnostic Implications." Clinical Chemistry 46, no. 1 (2000): 47–54. http://dx.doi.org/10.1093/clinchem/46.1.47.

Full text

Abstract:

Abstract Background: Patients with prostate cancer (PCa) show a lower ratio of free prostate-specific antigen (fPSA) to total PSA (tPSA) in serum than patients with benign prostatic hyperplasia (BPH). The patterns of the intracellular PSA isoforms in malignant and benign prostatic tissue have been studied as potential molecular reasons for this phenomenon. Methods: Prostatic tissue samples were obtained after cystoprostatectomy from patients with bladder cancer (n = 10), from BPH patients (transurethral resection of the prostate, n = 10; adenomectomy, n = 10), and from the cancerous and noncan

APA, Harvard, Vancouver, ISO, and other styles

43

Tkac, Jan, Veronika Gajdosova, Stefania Hroncekova, et al. "Prostate-specific antigen glycoprofiling as diagnostic and prognostic biomarker of prostate cancer." Interface Focus 9, no. 2 (2019): 20180077. http://dx.doi.org/10.1098/rsfs.2018.0077.

Full text

Abstract:

The initial part of this review details the controversy behind the use of a serological level of prostate-specific antigen (PSA) for the diagnostics of prostate cancer (PCa). Novel biomarkers are in demand for PCa diagnostics, outperforming traditional PSA tests. The review provides a detailed and comprehensive summary that PSA glycoprofiling can effectively solve this problem, thereby considerably reducing the number of unnecessary biopsies. In addition, PSA glycoprofiling can serve as a prognostic PCa biomarker to identify PCa patients with an aggressive form of PCa, avoiding unnecessary fur

APA, Harvard, Vancouver, ISO, and other styles

44

Stephan, Carsten, Kerstin Siemßen, Henning Cammann, et al. "Between-Method Differences in Prostate-Specific Antigen Assays Affect Prostate Cancer Risk Prediction by Nomograms." Clinical Chemistry 57, no. 7 (2011): 995–1004. http://dx.doi.org/10.1373/clinchem.2010.151472.

Full text

Abstract:

BACKGROUND To date, no published nomogram for prostate cancer (PCa) risk prediction has considered the between-method differences associated with estimating concentrations of prostate-specific antigen (PSA). METHODS Total PSA (tPSA) and free PSA were measured in 780 biopsy-referred men with 5 different assays. These data, together with other clinical parameters, were applied to 5 published nomograms that are used for PCa detection. Discrimination and calibration criteria were used to characterize the accuracy of the nomogram models under these conditions. RESULTS PCa was found in 455 men (58.3

APA, Harvard, Vancouver, ISO, and other styles

45

Kachuri, Linda, Rebecca E. Graff, Sonja I. Berndt, et al. "Abstract 1441: Genetic determinants of PSA levels improve prostate cancer screening." Cancer Research 82, no. 12_Supplement (2022): 1441. http://dx.doi.org/10.1158/1538-7445.am2022-1441.

Full text

Abstract:

Abstract Prostate-specific antigen (PSA) screening for prostate cancer (PCa) remains controversial due to poor sensitivity and specificity that lead to overdiagnosis and overtreatment. The aim of our study is to characterize genetic determinants of PSA levels in cancer-free men in order to personalize PCa screening. We hypothesize that test accuracy may be improved by accounting for PSA variation that is due to genetic factors and does not reflect PCa. We conducted the largest ever genome-wide association study (GWAS) of PSA in men without PCa (N=95,768; 85,924 predominantly European ancestry)

APA, Harvard, Vancouver, ISO, and other styles

46

Porcaro, Antonio B., Beatrice Caruso, Alessandro Terrin, et al. "The preoperative serum ratio of total prostate specific antigen (PSA) to free testosterone (FT), PSA/FT index ratio, and prostate cancer. Results in 220 patients undergoing radical prostatectomy." Archivio Italiano di Urologia e Andrologia 88, no. 1 (2016): 17. http://dx.doi.org/10.4081/aiua.2016.1.17.

Full text

Abstract:

Objectives: To evaluate associations of preoperative total prostate specific antigen (PSA) to free testosterone (FT), the PSA/FT index ratio, with features of pathology prostate cancer (PCA) and to investigate its prognostic potential in clustering the PCA population. Patients and methods: After excluding criteria, the records of 220 patients who underwent radical prostatectomy (RP) were retrospectively reviewed. Serum samples of PSA, total testosterone (TT) and FT were collected at 8.00 A.M., one month after biopsies and before RP. The PSA/FT ratio was computed in the population of patients w

APA, Harvard, Vancouver, ISO, and other styles

47

Wesseling, Sebastian, Carsten Stephan, Axel Semjonow та ін. "Determination of Non-α1-Antichymotrypsin-complexed Prostate-specific Antigen as an Indirect Measurement of Free Prostate-specific Antigen: Analytical Performance and Diagnostic Accuracy". Clinical Chemistry 49, № 6 (2003): 887–94. http://dx.doi.org/10.1373/49.6.887.

Full text

Abstract:

Abstract Background: A new assay measures prostate-specific antigen (PSA) not complexed to α1-antichymotrypsin (nACT-PSA) after removing PSA complexed to ACT by use of anti-ACT antibodies. We evaluated nACT-PSA and its ratio to total PSA (tPSA) as alternatives to free PSA (fPSA) and its ratio to tPSA in differentiating prostate cancer (PCa) and benign prostatic hyperplasia (BPH) in patients with tPSA of 2–20 μg/L. Methods: PSA in serum of 183 untreated patients with PCa and 132 patients with BPH was measured retrospectively on the chemiluminescence immunoassay analyzer LIAISON® (Byk-Sangtec Di

APA, Harvard, Vancouver, ISO, and other styles

48

Figueras, Marcel, Lourdes Mengual, Mercedes Ingelmo-Torres, et al. "Role of Liquid Biopsy in Progressive PSA Patients after Radical Prostatectomy." Diagnostics 14, no. 20 (2024): 2293. http://dx.doi.org/10.3390/diagnostics14202293.

Full text

Abstract:

Background/Objectives: Currently, the prediction of disease recurrence after radical prostatectomy (RP) in localized prostate cancer (PCa) relies on clinicopathological parameters, which lack accuracy in predicting clinical outcomes. This study focused on evaluating the utility of cfDNA levels and fragmentation patterns as prognostic biomarkers in progressive prostate-specific antigen (PSA) patients, including those with persistent PSA and biochemical recurrence (BR), after primary treatment in localized PCa patients. Methods: Twenty-nine high-risk localized PCa patients were enrolled in the s

APA, Harvard, Vancouver, ISO, and other styles

49

Carrot, Aurore, Reza-Thierry Elaidi, Olivier Colomban, et al. "Modeled Early Longitudinal PSA Kinetics Prognostic Value in Rising PSA Prostate Cancer Patients after Local Therapy Treated with ADT +/− Docetaxel." Cancers 14, no. 3 (2022): 815. http://dx.doi.org/10.3390/cancers14030815.

Full text

Abstract:

Background: In metastatic prostate cancer (PCa) patients, androgen-deprivation therapy (ADT) combined with chemotherapy or next-generation androgen receptor targeted agents is a new standard treatment. The objective of the present study is to assess longitudinal PSA kinetics during treatment using mathematical modeling, to identify the modeled PSA kinetic parameters able to exhibit early prognostic/predictive values. Methods: Phase III clinical trial dataset (NCT00764166) comparing ADT +/− docetaxel in 250 locally treated patients for PCa with rising PSA levels, who were at high risk of metast

APA, Harvard, Vancouver, ISO, and other styles

50

An, Hengqing, Ning Tao, Jia Li, et al. "Detection of Prostate Cancer Metastasis by Whole Body Magnetic Resonance Imaging Combined with Bone Scintigraphy and PSA Levels." Cellular Physiology and Biochemistry 40, no. 5 (2016): 1052–62. http://dx.doi.org/10.1159/000453161.

Full text

Abstract:

Background/Aims: The combined role of whole-body magnetic resonance imaging (WB-MRI), bone scintigraphy and prostate specific antigen (PSA) were considered in predicting metastases and prognosis of prostate cancer (PCa). Methods: Totally 38 PCa patients underwent WB-MRI, bone scintigraphy and PSA detections, and 34 benign prostate hyperplasia (BPH) patients were checked with PSA. Pearson correlations were performed to determine associations among PSA, apparent diffusion coefficient (ADC) and Gleason scoring. Specificity and sensitivity were for comparison of diagnostic accuracies. Patients' ba

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!